Work

Adjuvant pembrolizumab in clear cell renal cell carcinoma with high recurrence risk: A multicenter real-world study.

Year: 2026

Type: article

Study design: Observational Study

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.e16538

Authors: Liangyou Gu, Yicong Du, Shimiao Zhu, Bin Liu, Dongxing Wang, Yaohui Wang, Long He, Yongkun SUN, Qi Tang, Zhisong He

Institutions: Chinese PLA General Hospital, Peking University First Hospital, Second Hospital of Tianjin Medical University, Tianjin Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Peking University

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162689542

FWCI:

Cites:

Cited by:

Related to: